Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $210 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $502 | $0 | $342 | $145 |
| Gross Profit | -$502 | $0 | -$342 | $65 |
| % Margin | – | – | – | 31% |
| R&D Expenses | $46,996 | $30,291 | $23,688 | $8,370 |
| G&A Expenses | $21,614 | $7,518 | $5,504 | $3,896 |
| SG&A Expenses | $21,614 | $7,518 | $5,162 | $3,751 |
| Sales & Mktg Exp. | $0 | $0 | -$342 | -$145 |
| Other Operating Expenses | -$502 | $0 | $0 | $0 |
| Operating Expenses | $68,108 | $37,809 | $28,850 | $12,121 |
| Operating Income | -$68,610 | -$37,809 | -$29,192 | -$12,056 |
| % Margin | – | – | – | -5,741% |
| Other Income/Exp. Net | $7,179 | $1,504 | $1,482 | $2,869 |
| Pre-Tax Income | -$61,431 | -$36,305 | -$27,710 | -$9,187 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61,431 | -$36,305 | -$27,710 | -$9,187 |
| % Margin | – | – | – | -4,374.8% |
| EPS | -2.5 | -1.35 | -1.08 | -0.36 |
| % Growth | -85.2% | -25% | -200% | – |
| EPS Diluted | -2.5 | -1.35 | -1.08 | -0.36 |
| Weighted Avg Shares Out | 24,602 | 26,884 | 25,574 | 25,574 |
| Weighted Avg Shares Out Dil | 24,602 | 26,884 | 25,574 | 25,574 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,851 | $2,349 | $114 | $2 |
| Interest Expense | -$1,375 | $1,370 | $0 | $0 |
| Depreciation & Amortization | -$5,804 | $373 | $342 | $145 |
| EBITDA | -$68,610 | -$34,562 | -$27,368 | -$9,042 |
| % Margin | – | – | – | -4,305.7% |